|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016: CA Cancer J Clin. 66:7–30. 2016.
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Geller JI: Current standards of care and
future directions for ‘high-risk’ pediatric renal tumors:
Anaplastic Wilms tumor and Rhabdoid tumor. Urol Oncol. 34:50–56.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuroda N, Karashima T, Inoue K, Kasajima
A, Ohe C, Kawakami F, Mikami S, Matsuura K, Moriyama M, Nagashima
Y, et al: Review of renal cell carcinoma with rhabdoid features
with focus on clinical and pathobiological aspects. Pol J Pathol.
66:3–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Cancer Institute: Childhood
Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment
(PDQ®). Health professional version. 2002.
|
|
6
|
McGovern SL, Okcu MF, Munsell MF,
Kumbalasseriyil N, Grosshans DR, McAleer MF, Chintagumpala M,
Khatua S and Mahajan A: Outcomes and acute toxicities of proton
therapy for pediatric atypical teratoid/rhabdoid tumor of the
central nervous system. Int J Radiat Oncol Biol Phys. 90:1143–1152.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kralik SF, Ho CY, Finke W, Buchsbaum JC,
Haskins CP and Shih CS: Radiation necrosis in pediatric patients
with brain tumors treated with proton radiotherapy. AJNR Am J
Neuroradiol. 36:1572–1578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Elsayad K, Kriz J, Samhouri L, Haverkamp
U, Straeter R, Stummer W and Eich HT: Long-term survival following
additive radiotherapy in patients with atypical teratoid rhabdoid
tumors. Strahlenther Onkol. 192:569–581. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wellington K and Jarvis B: Silymarin: A
review of its clinical properties in the management of hepatic
disorders. BioDrugs. 15:465–489. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sozen H, Celik OI, Cetin ES, Yilmaz N,
Aksozek A, Topal Y, Cigerci IH and Beydilli H: Evaluation of the
protective effect of silibinin in rats with liver damage caused by
itraconazole. Cell Biochem Biophys. 71:1215–1223. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Flora K, Hahn M, Rosen H and Benner K:
Milk thistle (Silybum marianum) for the therapy of liver disease.
Am J Gastroenterol. 93:139–143. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dastpeyman M, Motamed N, Azadmanesh K,
Mostafavi E, Kia V, Jahanian-Najafabadi A and Shokrgozar MA:
Inhibition of silibinin on migration and adhesion capacity of human
highly metastatic breast cancer cell line, MDA-MB-231, by
evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1
and D4GDI. Med Oncol. 29:2512–2518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vue B, Zhang S, Zhang X, Parisis K, Zhang
Q, Zheng S, Wang G and Chen QH: Silibinin derivatives as
anti-prostate cancer agents: Synthesis and cell-based evaluations.
Eur J Med Chem. 109:36–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang
Z, Wang Z, Zhang D, Xue Y, Chen Y, et al: Chemopreventive and
chemotherapeutic effects of intravesical silibinin against bladder
cancer by acting on mitochondria. Mol Cancer Ther. 10:104–116.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li F, Ma Z, Guan Z, Chen Y, Wu K, Guo P,
Wang X, He D and Zeng J: Autophagy induction by silibinin
positively contributes to its anti-metastatic capacity via
AMPK/mTOR pathway in renal cell carcinoma. Int J Mol Sci.
16:8415–8429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Massacesi C, Di Tomaso E, Urban P, Germa
C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R
and Hirawat S: PI3K inhibitors as new cancer therapeutics:
Implications for clinical trial design. Onco Targets Ther.
9:203–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mundi PS, Sachdev J, McCourt C and
Kalinsky K: AKT in cancer: New molecular insights and advances in
drug development. Br J Clin Pharmacol. 82:943–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang SX, Polley E and Lipkowitz S: New
insights on PI3K/AKT pathway alterations and clinical outcomes in
breast cancer. Cancer Treat Rev. 45:87–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen H, Zhou L, Wu X, Li R, Wen J, Sha J
and Wen X: The PI3K/AKT pathway in the pathogenesis of prostate
cancer. Front Biosci (Landmark Ed). 21:1084–1091. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Foster K, Wang Y, Zhou D and Wright C:
Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell
survival. Cancer Chemother Pharmacol. 63:783–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Hai J, Cao M, Zhang Y, Pei S,
Wang J and Zhang Q: Silibinin ameliorates steatosis and insulin
resistance during non-alcoholic fatty liver disease development
partly through targeting IRS-1/PI3K/Akt pathway. Int
Immunopharmacol. 17:714–720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng N, Luo J and Guo X: Silybin
suppresses cell proliferation and induces apoptosis of multiple
myeloma cells via the PI3K/Akt/mTOR signaling pathway. Mol Med Rep.
13:3243–3248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garvin AJ, Re GG, Tarnowski BI,
Hazen-Martin DJ and Sens DA: The G401 cell line, utilized for
studies of chromosomal changes in Wilms' tumor, is derived from a
rhabdoid tumor of the kidney. Am J Pathol. 142:375–380.
1993.PubMed/NCBI
|
|
25
|
Krust B, El Khoury D, Soundaramourty C,
Nondier I and Hovanessian AG: Suppression of tumorigenicity of
rhabdoid tumor derived G401 cells by the multivalent HB-19
pseudopeptide that targets surface nucleolin. Biochimie.
93:426–433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Unland R, Borchardt C, Clemens D, Kool M,
Dirksen U and Frühwald MC: Analysis of the antiproliferative
effects of 3-deazaneoplanocin A in combination with standard
anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs.
26:301–311. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Megison ML, Gillory LA, Stewart JE, Nabers
HC, Mrozcek-Musulman E and Beierle EA: FAK inhibition abrogates the
malignant phenotype in aggressive pediatric renal tumors. Mol
Cancer Res. 12:514–526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang
T, Zhang L, Chen Y, Gao Y, Wang B, et al: Silibinin inhibits
β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis
via dual-blocking epithelial-mesenchymal transition and stemness.
Cell Signal. 25:2625–2633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang HR, Chen PN, Yang SF, Sun YS, Wu SW,
Hung TW, Lian JD, Chu SC and Hsieh YS: Silibinin inhibits the
invasion and migration of renal carcinoma 786-O cells in vitro,
inhibits the growth of xenografts in vivo and enhances
chemosensitivity to 5-fluorouracil and paclitaxel. Mol Carcinog.
50:811–823. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang L, Li L, Zeng J, Gao Y, Chen YL,
Wang ZQ, Wang XY, Chang LS and He D: Inhibitory effect of silibinin
on EGFR signal-induced renal cell carcinoma progression via
suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep.
28:999–1005. 2012.PubMed/NCBI
|
|
31
|
King D, Yeomanson D and Bryant HE: PI3King
the lock: Targeting the PI3K/Akt/mTOR pathway as a novel
therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol.
37:245–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wyatt LA, Filbin MT and Keirstead HS: PTEN
inhibition enhances neurite outgrowth in human embryonic stem
cell-derived neuronal progenitor cells. J Comp Neurol.
522:2741–2755. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen X, Wang YW, Xing AY, Xiang S, Shi DB,
Liu L, Li YX and Gao P: Suppression of SPIN1-mediated PI3K-Akt
pathway by miR-489 increases chemosensitivity in breast cancer. J
Pathol. 239:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pulido R: PTEN: A yin-yang master
regulator protein in health and disease. Methods. 77–78:3–10. 2015.
View Article : Google Scholar
|
|
35
|
Grunt TW and Mariani GL: Novel approaches
for molecular targeted therapy of breast cancer: Interfering with
PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 13:188–204.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rafael D, Doktorovová S, Florindo HF,
Gener P, Abasolo I, Schwartz S Jr and Videira MA: EMT blockage
strategies: Targeting Akt dependent mechanisms for breast cancer
metastatic behaviour modulation. Curr Gene Ther. 15:300–312. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen WC, Lai YA, Lin YC, Ma JW, Huang LF,
Yang NS, Ho CT, Kuo SC and Way TD: Curcumin suppresses
doxorubicin-induced epithelial-mesenchymal transition via the
inhibition of TGF-β and PI3K/AKT signaling pathways in
triple-negati breast cancer cells. J Agric Food Chem.
61:11817–11824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saletta F, Wadham C, Ziegler DS, Marshall
GM, Haber M, McCowage G, Norris MD and Byrne JA: Molecular
profiling of childhood cancer: Biomarkers and novel therapies. BBA
Clin. 1:59–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
